Self-reinforcing nanoplatform uniting pemetrexed, magnetic hyperthermia and PD-L1 blockade reshapes the tumor microenvironment and elicits combined antitumor immunity in lung adenocarcinoma
Source abstract
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide, and immune checkpoint blockade is often limited by an immunosuppressive tumor microenvironment (TME). To address these challenges, we developed a novel multifunctional nanoplatform, based on a mesoporous Fe 3 O 4 core and silica shell, co-loading pemetrexed and an anti-PD-L1 antibody (PD-L1&Pem@msNPs). The construct enables checkpoint-targeted delivery, alternating magnetic field (AMF)-triggered hyperthermia and controlled drug release, enabling a single-system chemo–immuno–magnetothermal regimen. We comprehensively investigated the physicochemical properties, magnetothermal performance, loading/conjugation, and release behavior, and validated cellular uptake and cytotoxicity in vitro. In subcutaneous and orthotopic lung tumor models, PD-L1&Pem@msNPs achieved superior tumor suppression and extended survival compared with control formulations. Mechanistically, transcriptomic profiling together with immunophenotyping demonstrated marked TME remodeling, with increased intratumoral T-cell representation accompanied by coordinated rewiring of macrophages status. Notably, longitudinal flow cytometry revealed a shift in T-cell states from an exhausted-intermediate (Tex-int) toward a progenitor-like (Tex-prog) phenotype, consistent with restoration of T-cell functionality under treatment. Collectively, PD-L1&Pem@msNPs provides an externally activatable, modular platform to remodel the TME and improve the therapeutic impact of PD-L1 blockade in lung cancer. • Magnetothermal-chemo-PD-L1 platform enhances target release and immunogenicity. • Reverses the T cell exhaustion and remodels the immunosuppressive TME. • Tumor-targeted co-delivery achieves strong antitumor efficacy and limited toxicity.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Immunotherapy and Biomarkers · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. Cancer statistics
2. Lung cancer10.1016/S0140-6736(21)00312-3 ↗
3. New promises and challenges in the treatment of advanced non-small-cell lung cancer10.1016/S0140-6736(24)01029-8 ↗
4. Toward personalized treatment approaches for non-small-cell lung cancer10.1038/s41591-021-01450-2 ↗
5. Lung cancer immunotherapy: progress, pitfalls, and promises10.1186/s12943-023-01740-y ↗
6. At the crossroads of immunotherapy for oncogene-addicted subsets of nsclc10.1038/s41571-022-00718-x ↗
7. Overcoming immunotherapy resistance in non-small cell lung cancer (Nsclc) - novel approaches and future outlook10.1186/s12943-020-01260-z ↗
8. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial10.1016/S1470-2045(20)30140-6 ↗
9. Updated analysis from keynote-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer10.1200/JCO.19.03136 ↗
10. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the sabr-comet phase ii randomized trial10.1200/JCO.20.00818 ↗
11. Pulmonary toxicity of immune checkpoint immunotherapy10.1172/JCI170503 ↗
12. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study10.2147/IJN.S186344 ↗
13. Immunomodulatory r848-loaded anti-pd-l1-conjugated reduced graphene oxide quantum dots for photothermal immunotherapy of glioblastoma10.3390/pharmaceutics16081064 ↗
14. Copper-coordination driven nano-frameworks for efficient colorectal cancer chemo-immunotherapy by suppression of cancer cell stemness
15. Mesoporous silicas in materials engineering: nanodevices for bionanotechnologies
16. Subnanometer local temperature probing and remotely controlled drug release based on azo-functionalized iron oxide nanoparticles10.1021/nl400188q ↗
17. Pore size and porosity dependent zeta potentials of mesoporous silica nanoparticles10.1021/acs.jpcc.0c04602 ↗
18. Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy10.1016/j.colsurfb.2020.110824 ↗
19. Mesoporous silica nanoparticles as an ideal platform for cancer immunotherapy: recent advances and future directions10.1002/adhm.202400323 ↗
20. Antibody stabilization for thermally accelerated deep immunostaining10.1038/s41592-022-01569-1 ↗
21. Targeted destruction of cancer stem cells using multifunctional magnetic nanoparticles that enable combined hyperthermia and chemotherapy10.7150/thno.38989 ↗
22. Intratumor heterogeneity: the rosetta stone of therapy resistance10.1016/j.ccell.2020.03.007 ↗
23. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution10.1016/j.ccell.2014.12.001 ↗
24. Releasing the brakes of tumor immunity with anti-pd-l1 and pushing its accelerator with l19-il2 cures poorly immunogenic tumors when combined with radiotherapy10.1136/jitc-2020-001764 ↗
25. Mitochondria-targeted multifunctional nanoparticles combine cuproptosis and programmed cell death-1 downregulation for cancer immunotherapy
26. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment10.1186/s12943-019-0974-6 ↗
27. Global characterization of t cells in non-small-cell lung cancer by single-cell sequencing10.1038/s41591-018-0045-3 ↗
28. Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity10.1126/sciadv.abc3646 ↗
29. Beyond cancer cells: targeting the tumor microenvironment with gene therapy and armed oncolytic virus10.1016/j.ymthe.2021.04.015 ↗
30. Metabolic interactions in the tumor microenvironment10.1016/j.tcb.2017.06.003 ↗
31. Histone lactylation bridges metabolic reprogramming and epigenetic rewiring in driving carcinogenesis: oncometabolite fuels oncogenic transcription10.1002/ctm2.1614 ↗
32. Nanodrug enhances post-ablation immunotherapy of hepatocellular carcinoma via promoting dendritic cell maturation and antigen presentation
33. Stem-like exhausted and memory cd8(+) t cells in cancer10.1038/s41568-023-00615-0 ↗
34. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell rna sequencing10.1186/s13073-023-01164-9 ↗
35. On the dependency of cellular protein levels on mrna abundance10.1016/j.cell.2016.03.014 ↗
36. Proteogenomics connects somatic mutations to signalling in breast cancer10.1038/nature18003 ↗
37. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses10.1038/nrg3185 ↗
38. Mast cells in the tumor microenvironment10.1007/978-3-030-49270-0_9 ↗
39. Focus on mast cells in the tumor microenvironment: current knowledge and future directions
40. Macrophages in immunoregulation and therapeutics10.1038/s41392-023-01452-1 ↗
41. Cd206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity10.1172/jci.insight.155022 ↗
42. Perspective on direction of control: cellular metabolism and macrophage polarization10.3389/fimmu.2022.918747 ↗
43. Developmental relationships of four exhausted cd8(+) t cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms10.1016/j.immuni.2020.04.014 ↗
44. Subsets of exhausted cd8(+) t cells differentially mediate tumor control and respond to checkpoint blockade10.1038/s41590-019-0312-6 ↗